286 related articles for article (PubMed ID: 19519883)
1. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer.
Azorsa DO; Gonzales IM; Basu GD; Choudhary A; Arora S; Bisanz KM; Kiefer JA; Henderson MC; Trent JM; Von Hoff DD; Mousses S
J Transl Med; 2009 Jun; 7():43. PubMed ID: 19519883
[TBL] [Abstract][Full Text] [Related]
2. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.
Hattori H; Skoulidis F; Russell P; Venkitaraman AR
Mol Cancer Ther; 2011 Apr; 10(4):670-8. PubMed ID: 21289082
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
4. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells.
Arora S; Bisanz KM; Peralta LA; Basu GD; Choudhary A; Tibes R; Azorsa DO
Gynecol Oncol; 2010 Sep; 118(3):220-7. PubMed ID: 20722101
[TBL] [Abstract][Full Text] [Related]
5. Depletion of RAD17 sensitizes pancreatic cancer cells to gemcitabine.
Fredebohm J; Wolf J; Hoheisel JD; Boettcher M
J Cell Sci; 2013 Aug; 126(Pt 15):3380-9. PubMed ID: 23687379
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition.
Venkatesha VA; Parsels LA; Parsels JD; Zhao L; Zabludoff SD; Simeone DM; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2012 Jun; 14(6):519-25. PubMed ID: 22787433
[TBL] [Abstract][Full Text] [Related]
7. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
Bhattacharjee V; Zhou Y; Yen TJ
Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
[TBL] [Abstract][Full Text] [Related]
8. The MAPK-activated protein kinase 2 mediates gemcitabine sensitivity in pancreatic cancer cells.
Köpper F; Binkowski AM; Bierwirth C; Dobbelstein M
Cell Cycle; 2014; 13(6):884-9. PubMed ID: 24556918
[TBL] [Abstract][Full Text] [Related]
9. hTERT-siRNA could potentiate the cytotoxic effect of gemcitabine to pancreatic cancer cells Bxpc-3.
Tan J; Zhou X; Zhu H
Exp Clin Transplant; 2012 Aug; 10(4):386-93. PubMed ID: 22757972
[TBL] [Abstract][Full Text] [Related]
10. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
11. High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells.
Henderson MC; Gonzales IM; Arora S; Choudhary A; Trent JM; Von Hoff DD; Mousses S; Azorsa DO
Mol Cancer Res; 2011 Jun; 9(6):724-32. PubMed ID: 21536687
[TBL] [Abstract][Full Text] [Related]
12. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
13. Wee1 is required to sustain ATR/Chk1 signaling upon replicative stress.
Saini P; Li Y; Dobbelstein M
Oncotarget; 2015 May; 6(15):13072-87. PubMed ID: 25965828
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
15. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776.
Engelke CG; Parsels LA; Qian Y; Zhang Q; Karnak D; Robertson JR; Tanska DM; Wei D; Davis MA; Parsels JD; Zhao L; Greenson JK; Lawrence TS; Maybaum J; Morgan MA
Clin Cancer Res; 2013 Aug; 19(16):4412-21. PubMed ID: 23804422
[TBL] [Abstract][Full Text] [Related]
17. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine triggers a pro-survival response in pancreatic cancer cells through activation of the MNK2/eIF4E pathway.
Adesso L; Calabretta S; Barbagallo F; Capurso G; Pilozzi E; Geremia R; Delle Fave G; Sette C
Oncogene; 2013 Jun; 32(23):2848-57. PubMed ID: 22797067
[TBL] [Abstract][Full Text] [Related]
19. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
Morgan MA; Parsels LA; Parsels JD; Lawrence TS; Maybaum J
Cell Cycle; 2006 Sep; 5(17):1983-8. PubMed ID: 16931916
[TBL] [Abstract][Full Text] [Related]
20. TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo.
Cao J; Yang J; Ramachandran V; Arumugam T; Deng D; Li Z; Xu L; Logsdon CD
PLoS One; 2015; 10(12):e0144969. PubMed ID: 26709920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]